Unity Biotechnology Inc (UBX) — Cash Flow-to-Debt Ratio
Unity Biotechnology Inc (UBX) has a Cash Flow-to-Debt Ratio of -0.21x as of March 2025, meaning its operating cash flow of $-6.36 Million could theoretically repay 0% of its total liabilities ($30.55 Million) in one year. See UBX working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Unity Biotechnology Inc Cash Flow-to-Debt Ratio (2016–2024)
Historical debt coverage capacity for Unity Biotechnology Inc across 9 annual periods. Also explore Unity Biotechnology Inc equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Unity Biotechnology Inc (2016–2024)
Year-by-year debt coverage analysis for Unity Biotechnology Inc. For market capitalisation and broader financial context, see UBX stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.67x | $-20.86 Million | $31.17 Million | ▲ +35.4% |
| 2023 | -1.04x | $-38.65 Million | $37.29 Million | ▼ -16.8% |
| 2022 | -0.89x | $-51.03 Million | $57.50 Million | ▼ -28.3% |
| 2021 | -0.69x | $-45.06 Million | $65.14 Million | ▲ +35.2% |
| 2020 | -1.07x | $-78.33 Million | $73.44 Million | ▲ +55.1% |
| 2019 | -2.37x | $-72.42 Million | $30.51 Million | ▲ +13.3% |
| 2018 | -2.74x | $-56.62 Million | $20.68 Million | ▲ +20.2% |
| 2017 | -3.43x | $-38.36 Million | $11.18 Million | ▼ -2791.0% |
| 2016 | -0.12x | $-16.40 Million | $138.18 Million | — |